Your Health Questions
Answered by Professionals

Still feeling depressed while on medication? There are several factors to consider, including misdiagnosis or coexisting conditions, too-short or too-low-dose trials, complex brain biology beyond serotonin, and sleep or lifestyle issues; treatment resistant depression usually means no improvement after at least two adequate antidepressant trials. Evidence-based next steps include switching or combining meds, augmentation, esketamine, TMS, ECT, and adding psychotherapy plus sleep and lifestyle strategies, with urgent help needed for suicidal thoughts; see the complete guidance below to understand options and which next steps may fit your situation.

There are several factors to consider. Depression is often more than a simple serotonin issue; neurotransmitters and mood are shaped by brain circuit dysfunction, chronic stress, inflammation, and hormone or diagnostic mismatches, which is why standard therapy or SSRIs may fall short. New medical steps include personalized medication strategies (such as SNRIs or bupropion), ketamine or esketamine, TMS, targeted psychotherapy, and evidence-based lifestyle changes, but which to choose depends on your symptoms, history, and labs. See below for specific next steps, cautions, and when to seek urgent care.

If you are still depressed despite therapy, medication, and lifestyle changes, personalized, data-driven care can help, including measurement-based symptom tracking, evidence-based digital tools, targeted treatments like TMS, ECT, and ketamine or esketamine, plus integrated medical screening and trauma-informed therapies matched to your needs. There are several factors to consider. See below for the key signs you may need a new plan and the specific next steps, safety guidance, and clinician questions that can shape your best path forward.

If you are still depressed despite treatment, there are several factors to consider, including possible misdiagnosis, suboptimal medication choice or dose, unaddressed sleep or substance issues, and biological drivers like inflammation. New research-backed options such as ketamine or esketamine, TMS, and carefully combined therapies with sleep and exercise can help, and emerging psychedelic-assisted therapy is under study; the right next step depends on your specific situation, so review the complete guidance below and seek urgent help if you feel unsafe.

If your depression is not improving, there are several factors to consider, including the wrong medication fit, too-low or too-short dosing, coexisting medical or mental health conditions, and life stressors, which together can point to treatment-resistant depression after two adequate trials. See below to understand more. New FDA drug trials and treatments like esketamine, faster glutamate-targeting medicines, evidence-backed augmentation, and options such as TMS and ECT provide actionable next steps, but the best path depends on reassessing diagnosis, optimizing meds, adding therapy, and addressing safety needs, with full details and doctor-ready questions below.

If your depression is not improving on treatment, there are several factors to consider: confirm you have had an adequate dose and duration, consider switching or combining medications and adding evidence-based psychotherapy, screen for medical causes or a different diagnosis, and explore research-clinic options like TMS, ketamine or esketamine, ECT, pharmacogenomic guidance, and clinical trials. Timing matters and safety comes first, so review the 4 to 12 week response window with your clinician and seek urgent help for suicidal thoughts; key step-by-step checklists and details that could change your next move are provided below.

Zuranolone for MDD is a newer, short 14-day oral treatment that works on the brain’s GABA system rather than serotonin, so it can reduce depressive symptoms within days and may help when standard antidepressants have not. Your next steps include confirming the diagnosis, reviewing current meds and side effects, discussing candidacy, safety including driving precautions and potential costs with your clinician, and knowing when to seek urgent help, especially for suicidal thoughts or inability to care for yourself; there are several factors to consider. See below to understand more.

Tenesmus is the ongoing urge to pass stool even when empty, most often caused by rectal inflammation (IBD, proctitis, infections), IBS hypersensitivity, constipation, or pelvic floor dysfunction, and rarely tumors; urgent signs include rectal bleeding, black stools, weight loss, fever, severe pain, or symptoms lasting more than 2 to 3 weeks. There are several factors to consider; see below to understand more and to learn which red flags and risk factors could change your next steps. Relief is cause specific, with options that calm inflammation, optimize stool consistency, manage IBS with diet and stress strategies, add pelvic floor therapy, review medications, treat infections, and use simple comfort measures and daily habits. For a practical plan, including when to consider tests like colonoscopy and how to tailor changes safely, see the complete answer below.

There are several factors to consider: ongoing flares can result from a mismatch between your medication and biology, smoldering inflammation that symptoms miss, too low drug levels, or non inflammatory look-alikes like IBS or infection; objective tests such as fecal calprotectin and therapeutic drug monitoring help pinpoint the cause. See below for key details that could change your next steps. New remote monitoring IBD trials use app based symptom tracking, at home stool tests, medication level optimization, and virtual specialist access to detect inflammation early, adjust therapy faster, reduce hospitalizations, and support switching among multiple drug classes when needed; seek urgent care for severe pain, high fever, heavy bleeding, or rapid weight loss.

IBD research studies now point to a proactive, personalized path to remission that goes beyond symptom relief, targeting deep healing through treat-to-target monitoring, advanced biologics and small-molecule drugs, and emerging precision medicine and microbiome approaches. If you are still flaring, there are several factors to consider, from hidden inflammation and drug antibodies to diet, lifestyle, and clinical trial options; see below for key warning signs, when to reassess with your GI, and practical next steps that could change your care plan.

New IBD medications in 2026 expand options for people still flaring, including next generation IL-23 inhibitors and new oral therapies like selective JAK inhibitors and S1P modulators, alongside more personalized, data-driven care aimed at deeper remission and mucosal healing. There are several factors to consider, including safety tradeoffs, monitoring, and clear signs it may be time to switch. See below for who benefits most, key differences between drugs, combination strategies, lifestyle and surgery considerations, and step-by-step next actions to take with your gastroenterologist that could change your care plan.

New head-to-head data show Skyrizi generally achieves higher endoscopic remission than Stelara, with similar or slightly higher clinical remission and comparable safety, especially after anti-TNF failure. There are several factors to consider; see below for the exact remission rates, durability, who tends to benefit from each, dosing logistics, safety nuances, and red flags that should guide your next steps with a gastroenterologist.

If you are still flaring with IBD despite treatment, medically regulated clinical trials can be the next step, offering access to new targeted therapies, close specialist monitoring, and often no-cost study care, and they are not a last resort. Whether a trial fits your situation depends on disease severity, past response or intolerance to medicines, eligibility and safety details such as placebo use and rescue plans, and knowing when symptoms need urgent care, so review the full guidance below to decide the right next steps with your doctor.

If you're still flaring with mild to moderate UC, new research studies may be a vital next step, offering access to targeted therapies and close monitoring that pursue symptom remission, endoscopic healing, less steroid use, and prevention of long-term complications. There are several factors to consider, including who should consider trials, safety oversight and placebo use, and practical steps to discuss with your gastroenterologist; see below for important details that could influence your next care decisions.

There are several factors to consider. Nutritional therapy trials for Crohn’s disease can be a smart next step when you are still flaring despite medication, complementing your current treatment with supervised, evidence-based diets like exclusive or partial enteral nutrition, the Crohn’s Disease Exclusion Diet, and other anti inflammatory approaches to reduce inflammation, support gut healing, improve quality of life, and sometimes reduce steroid dependence. See below for key details that could shape your next steps, including who is most likely to benefit, what the research shows, safety and monitoring, how to find trials, questions to ask your doctor, and which red flag symptoms need urgent care.

Still flaring on ulcerative colitis treatment? New oral clinical trials may be your next step, offering access to targeted pills being studied, including JAK inhibitors, S1P modulators, and TYK2 inhibitors, with close specialist monitoring, though benefits, risks, and eligibility vary and should be reviewed with your gastroenterologist. There are several factors to consider. See below for how to confirm active inflammation, what the trial process and costs involve, potential side effects and safety safeguards, and the urgent red flag symptoms so you can choose the right next step for your care.

Paid IBD clinical trials near you can be a sound next step if you are still flaring, offering access to new therapies, closer monitoring, and compensation when standard treatments fall short. There are several factors to consider, including eligibility, safety oversight, possible side effects or placebo, visit demands, and how to coordinate with your GI and find active studies; see details below to choose the right next step.

Small molecule IBD drugs are oral, targeted options that work inside immune cells and can help people with Crohn's disease or ulcerative colitis who keep flaring despite steroids, immunomodulators, or biologics. Key types include JAK inhibitors such as tofacitinib and upadacitinib and S1P modulators such as ozanimod, which may act quickly and avoid antibody issues. There are several factors to consider, including who is a good candidate, required monitoring, and risks like infections, shingles, cholesterol changes, and rare clots. See below for details that could affect your next steps, including how fast these drugs work, safety checklists, and when to seek urgent care.

If your child’s IBD is still flaring despite treatment, there are several factors to consider. Medication mismatch, ongoing hidden inflammation, growth changes, or more aggressive disease can stall healing, and pediatric IBD clinical trials offer access to new targeted therapies with careful safety monitoring. For how to know when to consider a trial, what tests and optimization steps to ask about, and urgent symptoms that need immediate care, see the complete answer below, as these details can shape your next steps.

There are several factors to consider: new UC data shows Rinvoq often delivers faster induction and higher early remission rates in biologic‑experienced patients, while Omvoh demonstrates strong 1 year maintenance among responders with a more targeted safety profile. The better choice depends on how quickly you need relief, pill vs infusion preference, prior treatment history, and cardiovascular risk given JAK inhibitor boxed warnings; see below for key trial numbers, safety nuances, and when a mechanism switch may help guide your next steps with your gastroenterologist.

Still flaring despite treatment? Several factors can keep IBD active, including immune pathway shifts, anti-drug antibodies, gut barrier injury, and microbiome imbalance, and promising investigative options include selective IL-23 inhibitors, S1P receptor modulators, next-generation JAK inhibitors, anti-TL1A therapies, and microbiome-based approaches. For the key action steps that could change your next move, see below, including when to use therapeutic drug monitoring and objective tests, how to consider clinical trials after prior failures, and which symptoms require urgent care.

Persistent IBD flares often result from incomplete or lost response to medication, microscopic inflammation, suboptimal dosing, or overlapping conditions, and clinical trials can offer access to cutting edge therapies, close specialist monitoring, and the possibility of better disease control. There are several factors to consider. See below for the exact tests to confirm inflammation, how to optimize current therapy and address nutrition, stress, and sleep, urgent red flags to act on, and the questions to ask your doctor about emerging options and whether an IBD clinical trial is right for you.

There are several factors to consider if your UC is still flaring despite treatment, including a poor medication fit, secondary loss of response, persistent inflammation, or non-UC causes like infection or IBS overlap. Next steps often include objective reassessment and either optimizing current therapy or switching classes, including discussing oral JAK inhibitors for UC such as tofacitinib or upadacitinib with appropriate screening and monitoring. Key safety considerations, red flag symptoms, and guidance on tests, drug levels, clinical trials, and when surgery is appropriate are detailed below, which can significantly influence the best path forward with your care team.

Persistent IBD flares despite medication often happen because the drug is targeting the wrong immune pathway, levels are too low or blocked by antibodies, there is fixed scarring, or symptoms are from non inflammatory conditions like IBS, bile acid diarrhea, SIBO, or infection. There are several factors to consider; see below to understand more, including precision medicine steps like therapeutic drug and antibody monitoring, treat to target biomarkers, earlier and better matched biologic or small molecule options, nutrition support, and when to seek urgent care, with key details and next step questions for your doctor outlined below.

Persistent ulcerative colitis flares despite microbiome therapy often mean active inflammation is still driving disease, the probiotic strains or doses are ineffective, diet and stress are undermining progress, or you need combination therapy with standard UC medications rather than microbiome approaches alone. Evidence based next steps include therapeutic drug monitoring, switching biologic classes, considering JAK or S1P inhibitors, and evaluating FMT or clinical trials, while watching for red flag symptoms that need urgent care. There are several factors and tests that can change your plan, see the complete details below.

IBD trials with no placebo group ensure every participant receives active treatment, which can be more ethical and practical for people still flaring after standard therapies, while also offering access to emerging drugs and closer monitoring. There are several factors to consider, including that these options are investigational, side effects and eligibility vary, and designs may compare new treatments to approved drugs or different doses, so see the details below to learn risks, who might be a candidate, and how to discuss next steps with your gastroenterologist.

IBD mucosal healing often stalls when inflammation persists despite symptom relief, the treatment is not the right fit or taken inconsistently, or hidden triggers like NSAIDs, smoking, stress, infections, and nutrient or protein deficits slow repair. Fastest routes to repair include optimized targeted therapy such as biologics or JAK inhibitors with therapeutic drug monitoring, objective tracking with fecal calprotectin, CRP, and colonoscopy, plus nutrition support and trigger reduction. There are several factors to consider, so see the complete details below to understand what could change your next steps.

If five antidepressants have not helped, this often means treatment-resistant depression, but it is not untreatable and may be driven by factors like misdiagnosis, medical conditions, inflammation, sleep disorders, or genetic differences in how you process meds. See below for critical details that can shape your next steps. Effective next moves include a full re-evaluation plus evidence-based options such as augmentation strategies, ketamine or esketamine, TMS, ECT, intensive psychotherapy, and targeted lifestyle supports; seek urgent help right away if you have suicidal thoughts.

Vagus nerve stimulation for IBD trials is a promising, nerve targeted approach that engages the brain gut axis to lower inflammation without broadly suppressing immunity, with early small studies in Crohn’s and ulcerative colitis showing reduced inflammatory markers, symptom relief, and some remissions using implanted or noninvasive devices, though it remains investigational. There are several factors to consider. See below to understand more about candidacy, potential side effects and surgical risks, access and insurance, and how to talk with your gastroenterologist about trial options that could shape your next steps.

If you are still having IBD symptoms despite treatment, IBD patient registries that track real-world outcomes over years can pinpoint which therapies sustain remission, support treat-to-target personalized care, improve safety monitoring, and reveal fixable gaps that lead to better results. There are several factors to consider, including when to recheck inflammation with labs or imaging, adjust dosing or combinations, check drug levels, address IBS overlap, or seek urgent care for red flags; see below for specific questions to ask your doctor and other key details that could change your next steps.